ヒトパピローマウイルス感染症パイプライン（グローバル市場分析）...市場調査レポートについてご紹介

1. Global Human Papillomavirus Infection Drug Market Overview
1.1 Market Overview
1.2 Clinical Pipeline Insight

2. Human Papillomavirus Infections Drug Clinical Trial Insight by Phase & Country
2.1 Unknown Phase
2.2 Research
2.3 Preclinical
2.4 Clinical
2.5 Phase-0
2.6 Phase-I
2.7 Phase-I/II
2.8 Phase-II
2.9 Phase-II/III
2.10 Phase-III

3. Marketed Human Papillomavirus Drug Profile
3.1 Gardasil
3.2 Cervarix
3.3 Zyclara
3.4 Intron A
3.5 Yallaferon
3.6 ReliFeron
3.7 Alferon N
3.8 Veregen/Polyphenon E
3.9 Dermojuventus

4. No Development Reported & Discontinued HPV Drug Profiles
4.1 No Development Reported
4.2 Discontinued
4.3 Market Withdrawal

5. Competitive Landscape
5.1 Advanced Viral Research
5.2 Biogen Idec
5.3 BioSphings
5.4 EyeGene
5.5 Helix BioPharma
5.6 Inviragen
5.7 MedImmune
5.8 Merck & Co
5.9 Valeant Pharmaceuticals

Figure 1- 1: HPV Infections Clinical Pipeline by Phase (%), 2014
Figure 1- 2: HPV Infections Clinical Pipeline by Phase (Number), 2014
Figure 1- 3: No Development Reported in HPV Infections Clinical Pipeline by Phase (%), 2014
Figure 1- 4: No Development Reported in HPV Infections Clinical Pipeline by Phase (Number), 2014
Figure 1- 5: Discontinued HPV Infections Clinical Pipeline by Phase (%), 2014
Figure 1- 6: Discontinued HPV Infections Clinical Pipeline by Phase (Number), 2014

Following Information For Each Drug Profile is Covered in More than 200 Tables in Report:

• Drug Profile Overview
• Active Indication
• Phase of Development
• Country for Clinical Trial
• Owner / Originator/ Licensee/Collaborator
• Administrative Route
• Drug Class